Executive Summary
A single $253,723 NASA contract to Lockheed Martin for Mars end-to-end service architectures reflects modest early-stage R&D commitment in space exploration. Neutral signal due to small value (0.0002% of LMT's ~$130B FY25 guidance), firm-fixed pricing, zero outlays, and 3-month duration limiting near-term revenue impact. Monitor for follow-on potential amid NASA's Mars focus, but materiality remains low for institutional portfolios.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from March 01, 2026.
Investment Signals (1)
- Lockheed secures NASA Mars R&D award (LOW)▲
$253k firm-fixed price contract under PSC AR12 aligns LMT with NASA's Fourth Capability Studies BAA for Mars architectures.
Risk Flags (1)
- Execution [LOW RISK]▼
Firm-fixed price on 3-month contract (Mar-May 2026) shifts cost overrun risk fully to Lockheed.
Opportunities (1)
- ◆
Base + all options fully obligated at $253k; ties to NASA Mars priorities could seed larger R&D pipelines.
Sector Themes (1)
- ◆
Small award via full/open competition highlights sustained Mars mission studies from Goddard SFC.
Watch List (1)
- 👁
{"entity"=>"Lockheed Martin Corp", "reason"=>"Captured sole contract; small size warrants tracking for Mars program scaling.", "trigger"=>"Follow-on awards >$1M or outlays >50% obligated"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Deobligations Alert
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals